Unlocking de novo antibody design with generative artificial intelligence
Shanehsazzadeh, A.; Bachas, S.; Kasun, G.; Sutton, J. M.; Steiger, A. K.; Shuai, R.; Kohnert, C.; Morehead, A.; Brown, A.; Chung, C.; Luton, B. K.; Diaz, N.; McPartlon, M.; Knight, B.; Radach, M.; Bateman, K.; Spencer, D. A.; Cejovic, J.; Kopec-Belliveau, G.; Haile, R.; Yassine, E.; McCloskey, C.; Natividad, M.; Chapman, D.; Stojanovic, L.; Rakocevic, G.; Hannum, G.; Yapici, E.; Moran, K.; Caguiat, R.; Abdulhaqq, S.; Guo, Z.; Klug, L. R.; Gander, M.; Meier, J.
Show abstract
Generative AI has the potential to redefine the process of therapeutic antibody discovery. In this report, we describe and validate deep generative models for the de novo design of antibodies against human epidermal growth factor receptor (HER2) without additional optimization. The models enabled an efficient workflow that combined in silico design methods with high-throughput experimental techniques to rapidly identify binders from a library of [~]106 heavy chain complementarity-determining region (HCDR) variants. We demonstrated that the workflow achieves binding rates of 10.6% for HCDR3 and 1.8% for HCDR123 designs and is statistically superior to baselines. We further characterized 421 diverse binders using surface plasmon resonance (SPR), finding 71 with low nanomolar affinity similar to the therapeutic anti-HER2 antibody trastuzumab. A selected subset of 11 diverse high-affinity binders were functionally equivalent or superior to trastuzumab, with most demonstrating suitable developability features. We designed one binder with [~]3x higher cell-based potency compared to trastuzumab and another with improved cross-species reactivity1. Our generative AI approach unlocks an accelerated path to designing therapeutic antibodies against diverse targets.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- AlphaBind, a Domain-Specific Model to Predict and Optimize Antibody-Antigen Binding Affinity 96%
- BioPhi: A platform for antibody design, humanization and humanness evaluation based on natural antibody repertoires and deep learning 96%
- In silico proof of principle of machine learning-based antibody design at unconstrained scale 96%
Similar papers in this journal
- Paraplume: A fast and accurate paratope prediction method provides insights into repertoire-scale binding dynamics 96%
- Generative and interpretable machine learning for aptamer design and analysis of in vitro sequence selection 95%
- When Two are Better than One: Modeling the Mechanisms of Antibody Mixtures 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.